Detail akcie READ-GENE online

Business Summary: Read Gene SA is a Poland-based company primarily engaged in the biotechnology sector. The Company is focused on research and technologies which aim is to detect, prevent and treat malignant tumors. The company's main segments are chemoprevention, clinical trials and genetic testing which are complementary to each other. Chemoprevention involves the use of natural or synthetic substances to inhibit, reverse or delay the process of cancer and in order to achieve that, the Company distributes supplements and food with products with a controlled content of micronutrients and vitamins. The Company provides clinical trials and offers them to corporate clients, mainly from the medical, pharmaceutical, chemical and biotechnology industries. The Company is also offering genetic testing services, including early lung cancer detection test, breast cancer test, colorectal cancer test or prostate cancer risk test.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Read Gene SA revenues increased 27% to PLN12.8M. Net loss decreased 26% to PLN996K. Revenues reflect Sales of Goods & Materials - Net increase of 44% to PLN59K. Lower net loss reflects G/L on Sale of Tangible & Intangible F increase from PLN47K to PLN146K (income), Other Operating Expense-Other decrease of 65% to PLN51K (expense), Interest Expense decrease of 17% to PLN330K (expense).